The offer of the ETP Securities described in these Final Terms in conditional on the ETP Securities being admitted to trading on the Main Market of the London Stock Exchange. The offer of these ETP Securities by the Issuer may be withdrawn without liability to the Issuer if the ETP Securities are not admitted to the Main Market of the London Stock Exchange on the business day listing is to become effective.

Final Terms dated: 30 October 2026

Leverage Shares Public Limited Company

(a public company incorporated with limited liability in Ireland)

LEI: 635400TLFJSNHVSOFH59

Issue of

2440 *Leverage Shares 3x Long Moderna (MRNA) ETP Securities*

pursuant to the

Collateralised Exchange Traded Securities Programme

(the "**ETP Securities**")

This document constitutes the Final Terms of the ETP Securities described herein.

The last day of validity of the Base Prospectus is 09 June 2027. The succeeding base prospectus will be published on the Issuer's website at https://leverageshares.com.

The following expressions shall have the following meanings:

"POATRs" means the Public Offers and Admissions to Trading Regulations 2024, as amended from time to time.

"PRM" means the Prospectus Rules: Admission to Trading on a Regulated Market sourcebook contained in the FCA Handbook, as amended from time to time.

PART A – CONTRACTUAL TERMS

Terms used herein shall have the meanings given to them in the terms and conditions set forth in the Base Prospectus dated 15 March 2024 which is incorporated by reference in the Base Prospectus dated 09 June 2026, and the supplement(s) to it dated 07 July 2026 (the "**Base Prospectus**" and the "**Base Prospectus Date**") which together constitute a base prospectus prepared in accordance with PRM. This document constitutes the Final Terms of the ETP Securities described herein and has been prepared for the purposes of completing the Base Prospectus in connection with the admission of the ETP Securities to trading on a regulated market in the United Kingdom for the purposes of the PRM, and must be read in conjunction with the Base Prospectus (and any supplement thereto).
Full information on Leverage Shares Public Limited Company (the "**Issuer**") and the offer of the ETP Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus (together with any supplement thereto) is available on the website of the Issuer at https://leverageshares.com/?page_id=16700. A summary of the ETP Securities to which these Final Terms relate is included as an Annex hereto. Terms used in these Final Terms bear the same meaning as in the Base Prospectus.

The particulars in relation to this issue of ETP Securities are as follows:

1.	Series of ETP Securities to which these Final Terms apply:	Leverage Shares 3x Long Moderna (MRNA) ETP Securities
2.	Tranche:	66
3.	Number of ETP Securities to which these Final Terms apply:	2440
4.	Issue Date:	30 October 2026
5.	Series Issue Date:	13 December 2021
6.	Issue Price:	USD 125.3247 per ETP Security
7.	Principal Amount:	USD 5.00 per ETP Security
8.	Maximum number of ETP Securities of this Series which may be issued:	1,000,000,000
9.	Minimum transferable number of ETP Securities:	One
10.	Trading Method:	Unit
11.	Relevant Currency:	USD
12.	Final Redemption Date:	9 November 2071
13.	Denomination:	Principal Amount
14.	Investment Objective:	To track the iSTOXX Leveraged 3x MRNA Index
15.	Income Series	Not Applicable
16.	Exposure Type:	Leveraged Exposure
17.	Leverage Factor:	3x
18.	Rebalance Period:	Daily
19.	Exchange:	NASDAQ
20.	Related Exchange:	All Exchanges
21.	Multiple Exchange:	Not Applicable
22.	Reference Asset:	The Reference Asset in respect of the ETP Securities is the following: Moderna Inc.
23.	Severe Disruption Event:	Not Applicable

24.	Condition 20 (Interest Amounts):	Not Applicable
	(i) Interest Payment Dates:	
25.	Form of ETP Securities:	Registered Notes: Global Note registered in the name of a nominee for a common depositary for Euroclear and Clearstream, Luxembourg. NGN Form: no
26.	Portfolio Administrator:	Flexinvest Limited
27.	Issuing and Paying Agent:	U.S. Bank Europe DAC
28.	Registrar:	U.S. Bank Europe DAC
29.	Portfolio Administration Agreement:	Flexinvest Portfolio Administration Agreement
30.	Terms and Conditions which apply to this Series:	Terms and Conditions Version 7
31.	Authorised Participant	As per Issuer's website
32.	Agency Agreement:	U.S. Bank Agency Agreement
33.	Operating Procedures Agreement:	LS Operating Procedures Agreement

The Issuer accepts the responsibility for the information contained in these Final Terms. Information in respect of the Reference Assets, the iSTOXX Leveraged 3x MRNA Index and www.stoxx.com/indices has been extracted from the website of the issuer of the Reference Assets (https://www.modernatx.com/), the website of NASDAQ (www.nasdaq.com) and the website of the sponsor of the Index (www.stoxx.com/indices). The Issuer confirms that such additional information has been accurately reproduced and that, so far as it is aware and is able to ascertain from information published by the issuer of the Reference Assets, NASDAQ and www.stoxx.com/indices no facts have been omitted which would render the reproduced information inaccurate or misleading.

PART B – OTHER INFORMATION

1. Listing and admission to trading:	Application has been made to the Financial Conduct Authority ("FCA") for the ETP Securities to which these Final Terms apply to be admitted to the Official List of the FCA. Application has been made to the London Stock Exchange for the ETP Securities to which these Final Terms apply to be admitted to trading on the Main Market of the London Stock Exchange.
Estimate of total expenses related to admission to trading:	Not Applicable

2. Interests of natural and legal persons involved in the issue

So far as the Issuer is aware, no person involved in the offer of the ETP Securities has an interest material to the offer.

Names and addresses of additional Paying Agent(s) (if any):	Not Applicable

3. Distribution

Offer to the public:	An offer of the ETP Securities to the public is made in reliance on the exemption from the prohibition on offers to the public in paragraph 6(a) of Part 1 of Schedule 1 of the POATRs.
Additional Selling Restrictions:	Not Applicable

4. Information about the past and the further performance of an Index and its volatility

Information about the past and further performance of the Index and its volatility can be obtained from:	Stoxx Limited www.stoxx.com/indices

5. Information concerning the Issuer of the Reference Asset and the Reference Asset

Address of Issuer of the Reference Asset:	Global Headquarters, 200 Technology Square, Cambridge, MA 02139
Country of Incorporation of the Issuer of the Reference Asset:	United States of America
Nature of Business of the Issuer of the Reference Asset:	As per the Base Prospectus.
Market on which the Reference Asset is admitted to trading:	NASDAQ
Description of the market in which the Reference Asset is traded:	The Reference Asset is traded on NASDAQ. NASDAQ is the second-largest stock exchange in the world by market capitalisation.
Date of establishment of market in which the Reference Asset is traded:	8 February 1971

How price information is published in respect of the market on which the Reference Asset is traded:	Pricing information is published on the website of NASDAQ and via third-party information providers.
An indication of daily trading volumes:	Information on daily trading volumes can be obtained from the website of NASDAQ and from other third party information providers.
Standing of the market on which the Reference Asset is traded and the market's regulatory authority:	NASDAQ is a leading global stock exchange. NASDAQ is registered with the United States Securities and Exchange Commission as a securities exchange.
Frequency of publication of prices of the Reference Asset:	Prices are published on a real-time basis by a number of third party information providers.
Main accounts relating to the Reference Asset:	The Reference Asset will be held by the Margin Loan Provider in the Margin Account.

6. Operational Information

ISIN Code:	XS3005160091
Common Code:	Not Applicable
Names and addresses of additional Paying Agent(s) (if any):	Not Applicable

7. Terms and Conditions of the Offer

Offer Price:	Issue Price
Time period, including any possible amendments, during which the offer will be open:	12 months from the Base Prospectus Date.
Conditions to which the offer is subject:	Offers of the ETP Securities are conditional upon their issue and, as between the Authorised Offeror(s) and their customers, any further conditions as may be agreed between them.
Description of the application process:	The ETP Securities are being made available by the Issuer for subscription only to Authorised Participants who have submitted a valid subscription order to the Issuer. New issuances of ETP Securities will generally be settled on the second London Business Day following the date on which a valid subscription order is received by the Issuer, together with the applicable fee, provided that such order is received prior to 2.30 p.m. London time on such day.
Description of possibility to reduce subscriptions and manner for refunding excess amount paid by applicants:	Not Applicable
Details of the minimum and/or maximum amount of application:	Not Applicable
Details of the method and time limited for paying up and delivering the ETP	The ETP Securities will be issued on the Issue Date against

Securities:	payment to the Issuer of the net subscription moneys
Manner in and date on which results of the offer are to be made public:	The Issuer will sell the ETP Securities to the Authorised Participant on issue. The Authorised Participant will act as a market maker and may also offer the ETP Securities to the public in over-the-counter transactions during the Offer Period. The Authorised Participant may hold the ETP Securities on its inventory. The number of ETP Securities issued will not vary based on the results of an offer and as a result, there is no necessity to notify the public of the results of any offer.
Procedure for exercise of any right of pre-emption, negotiability of subscription rights and treatment of subscription rights not exercised:	Not Applicable
Whether tranche(s) have been reserved for certain countries:	Not Applicable
Process for notification to applicants of the amount allotted and the indication whether dealing may begin before notification is made:	Not Applicable
Amount of any expenses and taxes specifically charged to the subscriber or purchaser:	Not Applicable
Name(s) and address(es), to the extent known to the Issuer, of the placers in the various countries where the offer takes place.	None
Name and address of financial intermediary/ies authorised to use the Base Prospectus, as completed by these Final Terms (the "**Authorised Offerors**"):	Each Authorised Participant expressly named as an Authorised Offeror on the Issuer's website (www.leverageshares.com).
Prohibition of Sales to UK Retail Investors:	Not Applicable
8. Intended to be held in a manner which would allow Eurosystem eligibility:	No. Whilst the designation is specified as "No" at the date of these Final Terms, should the Eurosystem eligibility criteria be amended in the future such that the Notes are capable of meeting them the Notes may then be deposited with one of the ICSDs as common safekeeper and registered in the name of a nominee of one of the ICSDs acting as common safekeeper. Note that this does not necessarily mean that the Notes will then be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem at any time during their life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met.